Galectin Therapeutics Inc is a clinical stage biopharmaceutical company. The company is engaged in drug research and development to create new therapies for fibrotic disease and cancer.
| Website: | www.galectintherapeutics.com |
| Email: | ktaylor@rife.com |
| Main Phone: | +1 678 620-3186 |
| Address: | 4960 Peachtree Industrial Boulevard |
| Address 2: | Suite 240 |
| State: | GA |
| City / Town: | Norcross |
| Country: | USA |
| Postal Code: | 30071 |
| Exchange: | NSC |
| CEO: | Harold H. Shlevin |
| Employees: | 7 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
| Last Price 6.12 | Change $ -0.5 | Change % -7.55 | Tick N/A |
| Bid 6.12 | Bid Size 300.00 | Ask 6.13 | Ask Size 100.00 |
| Open 6.65 | High 6.67 | Low 5.98 | Prev Close 6.62 |
| Last Trade | Volume 790,447 | 52 Wk Hi 9.49 | 52 Wk Low 1.28 |
| Market Cap 250.4 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 40,913,855.00 | EPS (TTM) -0.43 | PE Ratio N/A | Exchange NCM |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 48 | 56 |
| Number of Buys | 21 | 27 |
| Number of Sells | 27 | 29 |
| Net Activity | -532054 | -661893 |
| Last 10 Buys | Shares |
|---|---|
| Kevin D. Freeman | 1,000 |
| Kevin D. Freeman | 1,000 |
| Marc Rubin | 1,000 |
| Kevin D. Freeman | 1,000 |
| Kevin D. Freeman | 1,000 |
| Theodore H. Zucconi | 1,000 |
| Arthur R. Greenberg | 1,000 |
| Peter G. Traber | 1,000 |
| Kevin D. Freeman | 1,000 |
| Peter G. Traber | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Harold H. Shlevin | 1,000 |
| James C. Czirr | 1,000 |
| James C. Czirr | 1,000 |
| James C. Czirr | 1,000 |
| James C. Czirr | 1,000 |
| Jack W. Callicutt | 1,000 |
| Harold H. Shlevin | 1,000 |
| Jack W. Callicutt | 1,000 |
| Harold H. Shlevin | 1,000 |
| Jack W. Callicutt | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 12 | 12 | 12 | 12 |
| Low Target Price Estimate | 5 | 5 | 5 | 5 |
| Mean Target Price Estimate | 8.33 | 8.33 | 8.33 | 8.33 |
| Standard Deviation | 3.51 | 3.51 | 3.51 | 3.51 |
| Date of Most Recent Estimate | 05/31/18 | 05/31/18 | 05/15/18 | 05/31/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-15 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-06-15 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-14 |
| 4/A | Amendment to a previously filed Form 4 | 1 | 2018-06-14 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-14 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-14 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-14 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-12 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-12 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-12 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 3 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1 | 1 |
© 2018 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
